Pfizer Corporation

Pharmacia & Upjohn

Pfizer Products Inc.

Patrick Robert Verhoest

Christopher John Helal

Thomas Allen Chappie

Nandini Chaturbhai Patel

Matthew Merrill Hayward

Travis T Wager

Michael Aaron Brodney

Simone Sciabola

Jamison Bryce Tuttle

Bethany Lyn Kormos

Christopher Ryan Butler

Antonia Friederike Stepan

Erik Alphie LaChapelle

Laura Ann McAllister

Martin Youngjin Pettersson

Jaclyn Louise Henderson

Douglas Scott Johnson

Lei Zhang

Kristine E Frank

Jian-Min Fu

Michael D Ennis

Steven Victor O'Neil

Robert Louis Hoffman

Joseph Michael Young

Jeffrey W Corbett

Matthew Richard Reese

Adam Matthew Gilbert

Paul Galatsis

Ravi G Kurumbail

Gregory Wayne Kauffman

Bruce Nelsen Rogers

Michael Eric Green

Amy Beth Dounay

Justin Ian Montgomery

John Michael Humphrey

Christopher William Am Ende

Erik Alphie Lachapelle

Brian Thomas O'Neill

Chakrapani Subramanyam

Christopher John O'Donnell

Elizabeth Mary Beck

Dafydd Rhys Owen

Matthew Forrest Sammons

Karen Jean Coffman

Qingyi Yang

Tuan Phong Tran

Cory Michael Stiff

Michelle Marie Claffey

Damien Webb

Suobao Rong

Rayomand Jal Unwalla

Dennis J Hoover

Xiaojing Yang

James Thomas Anderson

Michelle Renee Garnsey

Ramalakshmi Yegna Chandrasekaran

Vinod Dipak Parikh

Xinjun J Hou

Eugene Lvovich Piatnitski Chekler

Liuqing Wei

Eddie Yang

Joseph Walter Tucker

Caroline Proulx-Lafrance

Peter Justin Mikochik

John Charles Murray

Christopher John O'donnell

Eugene Lvovich Chekler

Jotham Wadsworth Coe

Scot Richard Mente

Neelu Kaila

Edmund Lee Ellsworth

Tarek A Samad

Jeffrey Allen Pfefferkorn

Joseph Scott Warmus

Yuan Zhang

Michael L Vazquez

Mihir D Parikh

Jinshan Michael Chen

Anthony P Ricketts

Kapildev Kashmirilal Arora

Luis Angel Martinez-Alsina

Natasha Mariam Kablaoui

William Paul Esler

Albert Myung Kim

Bruce Kipp Erickson

David P Thompson

Xinmin Gan

Jamison Byrce Tuttle

Arthur James Bergman

James M Duerr

Neeta Balkrishan Amin

Roberto Arnaldo Calle

Danica Antonia Rankic

Matthew Francis Dunn

Colin Richard Rose

Romelia Del Carmen Salomon Ferrer

Laura Ann Mcallister

Steven Victor O'neil

A method for treating fatty liver disease and related diseases or disorders with a therapeutically effective amount of a composition comprising from about 25 mg to about 1200 mg of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or a pharmaceutically acceptable salt thereof, and from about 5 mg to about 40 mg of 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or a pharmaceutically acceptable salt thereof.

Combinations for treatment of NAFLD/NASH and related diseases

The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents A, R, R, R, R, R, Rand n are as defined herein. The inventions also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds and methods of preparing the compounds.

Tricyclic compounds and their use as phosphodiesterase inhibitors

The invention relates to compounds of Formula I&#x2033; wherein R, R, R, R, p, q and q' are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

Nitrile-containing antiviral compounds

The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R, R, R, R, R, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression. 

6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands

The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R, Rand Rare as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy. 

Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors

Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing them, and therapeutic uses thereof.

Pyrrolo[2,3-d]pyrimidine derivatives

The present invention provides, in part, heterocyclic spiro compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

Heterocyclic spiro compounds as MAGL inhibitors

The present invention is directed to PDE4B inhibitors of Formula I: (I) or a pharmaceutically acceptable salt thereof, wherein the substituents R, R, R, and Rare as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds. 

6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors

The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R, R, R, R, and b are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.

Imidazopyridazine compounds

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors

Growing community of inventors

Newton, MA, United States of America

Patrick Robert Verhoest